ArticleCancers2023

Blinatumomab and Inotuzumab Ozogamicin Sequential Use for the Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia: A Real-Life Campus All Study.

Nicola Stefano Fracchiolla et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.